Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

To ensure the study is broadly representative of primary care clinical practice, minimal inclusion and exclusion criteria are imposed with the main exclusion criteria relating to contraindications to the prescription of Selincro® and reflecting the indication wording in the SmPC. Inclusion Criteria: * The patient has alcohol dependence diagnosed according to ICD-10. * The patient has had a high DRL in the 4 weeks preceding the Screening Visit. * The patient is a man or woman, aged ≥18 years. * The patient provides a stable address and telephone number. Exclusion Criteria: * The patient has one or more contraindications to the prescription of Selincro®: * hypersensitivity to the active substance or to any of the excipients * taking opioid analgesics * current or recent opioid addiction * acute symptoms of opioid withdrawal * recent use of opioids suspected * severe hepatic impairment (Child-Pugh classification) * severe renal impairment (eGFR \<30 ml/min per 1.73 m2) * a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures, or delirium tremens) * The patient has had \<6 HDDs (defined by the European Medicines Agency as a day with an alcohol consumption \>60g for men or \>40g for women) in the 4 weeks preceding the Screening Visit. * The patient has physical alcohol withdrawal symptoms and requires immediate detoxification for which inpatient treatment is required. * The patient is currently participating or has recently (in the 4 weeks preceding the Screening Visit) participated in a treatment or support programme for alcohol-use disorders, including Alcohol Anonymous, detoxification treatment, and treatment of alcohol withdrawal symptoms, or the patient is already taking nalmefene or has taken nalmefene in the 6 months preceding the Screening Visit.